Mesa Laboratories (MLAB) reported fiscal second-quarter 2027 revenue of $62.336 million, up 2.6% from the prior-year quarter. Net income rose 75.3% to $4.341 million, while diluted earnings per share were $0.75.
The company issued fiscal 2027 guidance for revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million.
- Operating income increased 77.6% to $8.388 million.
- Second-quarter revenue by division included $25.342 million for Sterilization and Disinfection Control, $14.050 million for Calibration Solutions, $12.779 million for Biopharmaceutical Development and $10.165 million for Clinical Genomics.
- Mesa repaid $11.406 million of debt and reported a total net leverage ratio of 1.75 at September 30, 2026.
- The board authorized a new share repurchase program of up to $40 million, expiring December 31, 2028.
- The savings plan is expected to reduce annualized operating costs by about $9.3 million, with approximately $4.3 million planned for reinvestment.
$MLAB Insider Trading Activity
$MLAB insiders have traded $MLAB stock on the open market 9 times in the past 6 months. Of those trades, 2 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $MLAB stock by insiders over the last 6 months:
- JOHN JAMES SULLIVAN sold 7,093 shares for an estimated $800,090
- SIDDHARTHA KADIA (President and CEO) purchased 7,093 shares for an estimated $800,090
- JOHN SAKYS (CFO) has made 0 purchases and 2 sales selling 4,050 shares for an estimated $376,871.
- BRIAN DAVID ARCHBOLD (SVP Operations) has made 0 purchases and 2 sales selling 3,667 shares for an estimated $341,745.
- R TONY TRIPENY purchased 900 shares for an estimated $102,321
- LYNDSEY ELIZABETH CRENNEN (CAO) has made 0 purchases and 2 sales selling 560 shares for an estimated $51,509.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MLAB Hedge Fund Activity
We have seen 83 institutional investors add shares of $MLAB stock to their portfolio, and 64 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WASATCH ADVISORS LP added 271,461 shares (+234.7%) to their portfolio in Q3 2026, for an estimated $35,273,642
- SELECT EQUITY GROUP, L.P. removed 235,885 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $23,482,351
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 130,323 shares (+inf%) to their portfolio in Q3 2026, for an estimated $16,934,170
- ABERDEEN GROUP PLC added 101,100 shares (+inf%) to their portfolio in Q3 2026, for an estimated $13,136,934
- JACOBS LEVY EQUITY MANAGEMENT, INC added 86,421 shares (+194.6%) to their portfolio in Q2 2026, for an estimated $8,603,210
- FMR LLC added 82,387 shares (+1273.4%) to their portfolio in Q2 2026, for an estimated $8,201,625
- ROYCE & ASSOCIATES LP removed 73,797 shares (-65.1%) from their portfolio in Q3 2026, for an estimated $9,589,182
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
